Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 4/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.54 |
| ▸ | RELA | Q04206 | 2/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 8/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.45 |
| ▸ | PGR | P06401 | 6/20 | 0.45 |
| ▸ | AR | P10275 | 6/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.43 |
| ▸ | FNTB | P49356 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9619163 | 1.00 | NFKB1 (0.54) | NFKB1NFKB2RELAKCNH2HIF1A | |
| SCHEMBL8192700 | 1.00 | NFKB1 (0.54) | NFKB1NFKB2RELAKCNH2HIF1A | |
| SCHEMBL8207710 | 1.00 | NFKB1 (0.54) | NFKB1NFKB2RELAKCNH2HIF1A | |
| SCHEMBL3083179 | 1.00 | NFKB1 (0.54) | NFKB1NFKB2RELAKCNH2HIF1A | |
| SCHEMBL10419014 | 1.00 | NFKB1 (0.54) | NFKB1NFKB2RELAKCNH2HIF1A | |
| Methyl Alcohol SCHEMBL9756756 | 0.99 | NFKB1 (0.54) | NFKB1NFKB2RELAKCNH2HIF1A | |
| SCHEMBL8470202 | 0.93 | NFKB1 (0.46) | NFKB1NFKB2RELAKCNH2HIF1A | |
| SCHEMBL8470203 | 0.93 | NFKB1 (0.46) | NFKB1NFKB2RELAKCNH2HIF1A | |
| SCHEMBL2556587 | 0.90 | NFKB1 (0.56) | NFKB1NFKB2RELAKCNH2HIF1A | |
| SCHEMBL8203795 | 0.89 | NFKB1 (0.44) | NFKB1NFKB2RELAKCNH2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6090794-A | ADMINISTERING HEPARIN AND AN ANGIOSTATIC STEROID | THE GENERAL HOSPITAL CORPORATION (US) | 2000-07-18 | — | — | US | claimed |
| EP-0533703-B1 | Use of steroids for the inhibition of angiogenesis | ALCON LAB INC (US) | 2000-03-15 | — | — | EP | claimed |
| EP-0489779-B1 | OPHTHALMIC COMPOSITION | ALCON LAB INC (US) | 1998-01-28 | — | — | EP | claimed |
| US-5407926-A | Administering angiostatic steroid with glucocorticoid, carrier | ALCON LABORATORIES, INC. (US) | 1995-04-18 | — | — | US | claimed |
| EP-0371617-B1 | Use of angiostatic steroids in the manufacture of a medicament for controlling ocular hypertension | ALCON LAB INC (US) | 1994-06-08 | — | — | EP | claimed |
| EP-0477195-A1 | SURAMIN TYPE COMPOUNDS AND ANGIOSTATIC STEROIDS TO INHIBIT ANGIOGENESIS | THE UPJOHN COMPANY (US) | 1992-04-01 | — | — | EP | claimed |
| WO-1991019731-A1 | STEROIDS WHICH INHIBIT ANGIOGENESIS | THE UPJOHN COMPANY (US) | 1991-12-26 | — | — | WO | claimed |
| WO-1990015816-A1 | SURAMIN TYPE COMPOUNDS AND ANGIOSTATIC STEROIDS TO INHIBIT ANGIOGENESIS | THE UPJOHN COMPANY (US) | 1990-12-27 | — | — | WO | claimed |
| US-4876250-A | Methods for controlling ocular hypertension with angiostatic steroids | ALCON LABORATORIES, INC. (US) | 1989-10-24 | — | — | US | claimed |
| EP-4108248-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | Biomed Valley Discoveries, Inc. (US) | 2022-12-28 | — | — | EP | disclosed |
| US-20220378852-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | THE JOHNS HOPKINS UNIVERSITY | 2022-12-01 | — | — | US | disclosed |
| US-11390600-B2 | Crystalline forms of C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3730146-B1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-05-04 | — | — | EP | disclosed |
| US-11033621-B2 | Combination therapies targeting tumor-associated stroma or tumor cells | BIOMED VALLEY DISCOVERIES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| WO-1990012577-A2 | TOPICAL ANTI-ANGIOGENIC AS HAIR GROWTH INHIBITORS | THE UPJOHN COMPANY (US) | 1990-11-01 | — | — | WO | disclosed |
| US-4876250-A | Methods for controlling ocular hypertension with angiostatic steroids | ALCON LABORATORIES, INC. (US) | 1989-10-24 | — | — | US | disclosed |
| US-4771042-A | Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments | THE UPJOHN COMPANY (US) | 1988-09-13 | — | — | US | disclosed |
| EP-0221705-A1 | Tetrahydro angiostatic steroids | THE UPJOHN COMPANY (US) | 1987-05-13 | — | — | EP | disclosed |
| WO-1987002672-A1 | TETRAHYDRO ANGIOSTATIC STEROIDS | THE UPJOHN COMPANY (US) | 1987-05-07 | — | — | WO | disclosed |
| US-4088537-A | BIOTRANSFORMATION | THE UPJOHN COMPANY (US) | 1978-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220378852-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | HCCS, MKI67, PBK | NFKB1 1518/4885NFKB2 700/4885RELA 647/4885 |
| US-11390600-B2 | Crystalline forms of C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | NFKB1 2895/4885NFKB2 2728/4885RELA 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.